• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中重度银屑病的治疗目标和治疗应答评估:专家意见文件。

Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document.

机构信息

Department of Dermatology, Hospital General Universitario de Alicante-ISABIAL-UMH, Alicante, Spain.

Department of Dermatology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria La Princesa (IIS-IP), Madrid, Spain.

出版信息

Ann Med. 2021 Dec;53(1):1727-1736. doi: 10.1080/07853890.2021.1986637.

DOI:10.1080/07853890.2021.1986637
PMID:34601988
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8491706/
Abstract

OBJECTIVE

To critically analyse and define therapeutic objectives, response to treatment evaluation and related decisions in psoriasis.

METHODS

Expert consensus meetings, a systematic and narrative reviews and a collaborative Delphi procedure were carried out. A steering committee from the Spanish Group of Psoriasis was established who based on the reviews generated a set of related statements. Subsequently, a group of 40 experts tested their agreement with the statements, through 3 Delphi rounds.

RESULTS

We found a great variability in clinical guidelines regarding to the definition of treatment goal and the response. In general, treatment failure was considered if a PASI50 is not achieved. The panel of experts agreed on (1) clearly differentiate between ideal and a realistic goals when establishing the therapeutic goal in moderate to severe psoriasis; (2) treatment goals should be in general established regardless of the type of drug for psoriasis; (3) treatment failure if PASI75 response is not reached; (4) an absolute PASI is in general preferred to the rate of PASI improvement from baseline; (5) disease characteristics, patients and physicians opinions/needs and treatment adherence influence treatment goals.

CONCLUSIONS

A clear treatment decision making framework is vital to improve management of psoriasis.KEY MESSAGESPsoriasis characteristics, patients and physicians opinions/needs and treatment adherence influence treatment goals.Different disease indexes could be used to assess treatment response but absolute PASI is preferredIn general psoriasis treatment failure should be considered if PASI75 response is not reached.

摘要

目的

批判性分析和定义银屑病的治疗目标、治疗反应评估及相关决策。

方法

采用专家共识会议、系统评价和叙述性综述以及协作 Delphi 程序。成立了西班牙银屑病小组指导委员会,该委员会基于综述结果生成了一系列相关陈述。随后,由 40 名专家组成的专家组通过 3 轮 Delphi 对这些陈述进行了一致性测试。

结果

我们发现,临床指南在治疗目标和反应的定义方面存在很大差异。一般来说,如果 PASI50 未达到,则认为治疗失败。专家组一致认为:(1)在中重度银屑病中制定治疗目标时,应明确区分理想和现实目标;(2)一般应根据药物类型为银屑病设定治疗目标;(3)如果未达到 PASI75 反应,则视为治疗失败;(4)一般来说,更倾向于使用绝对 PASI,而不是从基线改善的 PASI 率;(5)疾病特征、患者和医生的意见/需求以及治疗依从性影响治疗目标。

结论

明确的治疗决策框架对于改善银屑病的管理至关重要。

关键信息

银屑病的特征、患者和医生的意见/需求以及治疗依从性影响治疗目标。可以使用不同的疾病指标来评估治疗反应,但更倾向于使用绝对 PASI。一般来说,如果 PASI75 反应未达到,则应考虑治疗失败。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64cd/8491706/415b59ee63d0/IANN_A_1986637_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64cd/8491706/415b59ee63d0/IANN_A_1986637_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64cd/8491706/415b59ee63d0/IANN_A_1986637_F0001_C.jpg

相似文献

1
Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document.中重度银屑病的治疗目标和治疗应答评估:专家意见文件。
Ann Med. 2021 Dec;53(1):1727-1736. doi: 10.1080/07853890.2021.1986637.
2
Definition of treatment goals for moderate to severe psoriasis: a European consensus.中重度银屑病治疗目标的定义:欧洲共识。
Arch Dermatol Res. 2011 Jan;303(1):1-10. doi: 10.1007/s00403-010-1080-1. Epub 2010 Sep 21.
3
Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology.中重度银屑病评估与治疗的共识文件:西班牙皮肤病学会和性病学会银屑病专家组。
J Eur Acad Dermatol Venereol. 2016 Mar;30 Suppl 2:1-18. doi: 10.1111/jdv.13542.
4
Treatment goals for moderate to severe psoriasis: an Australian consensus.中重度银屑病的治疗目标:澳大利亚共识。
Australas J Dermatol. 2013 May;54(2):148-54. doi: 10.1111/ajd.12014. Epub 2013 Jan 18.
5
Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies - Adult patients.澳大利亚共识:靶向治疗时代中重度银屑病的治疗目标 - 成人患者。
Australas J Dermatol. 2023 Nov;64(4):476-487. doi: 10.1111/ajd.14138. Epub 2023 Jul 28.
6
Redefining the therapeutic objective in psoriatic patients candidates for biological therapy.重新定义适合生物治疗的银屑病患者的治疗目标。
J Dermatolog Treat. 2018 Jun;29(4):334-346. doi: 10.1080/09546634.2017.1395794. Epub 2017 Nov 21.
7
An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals.使用银屑病治疗目标的欧洲共识计划标准评估阿达木单抗在三项 III 期临床试验中的疗效。
Br J Dermatol. 2013 Feb;168(2):374-80. doi: 10.1111/j.1365-2133.2012.11214.x. Epub 2012 Dec 13.
8
Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management.泛发性脓疱型银屑病:关于临床病程、诊断、治疗目标及疾病管理的全球德尔菲共识
J Eur Acad Dermatol Venereol. 2023 Apr;37(4):737-752. doi: 10.1111/jdv.18851. Epub 2023 Feb 4.
9
Implementing treatment goals for successful long-term management of psoriasis.实现治疗目标,以成功长期管理银屑病。
J Eur Acad Dermatol Venereol. 2012 Mar;26 Suppl 2:12-20. doi: 10.1111/j.1468-3083.2011.04411.x.
10
Management goals of type 1 Gaucher disease in South Africa: An expert Delphi consensus document on good clinical practice.南非 1 型戈谢病的管理目标:关于良好临床实践的专家德尔菲共识文件。
PLoS One. 2023 Aug 22;18(8):e0290401. doi: 10.1371/journal.pone.0290401. eCollection 2023.

引用本文的文献

1
Beyond Skin Clearance: Personalized Strategies for DLQI Improvement in Psoriasis -Insights From a Shanghai Prospective Cohort.超越皮肤清除率:上海前瞻性队列研究对改善银屑病患者皮肤病生活质量指数的个性化策略启示
Psoriasis (Auckl). 2025 Aug 13;15:373-387. doi: 10.2147/PTT.S534881. eCollection 2025.
2
Balancing efficacy and hepatotoxicity: a comprehensive review of oral medications in psoriasis management.平衡疗效与肝毒性:银屑病治疗中口服药物的综合综述
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun 25. doi: 10.1007/s00210-025-04334-1.
3
Investigation of the Efficacy and Safety of Xeligekimab (GR1501) in Patients with Moderate-to-Severe Plaque Psoriasis: A Multicenter, Randomized, Double-Blind Phase II Clinical.

本文引用的文献

1
Patient-physician discrepancy in the perception of immune-mediated inflammatory diseases: rheumatoid arthritis, psoriatic arthritis and psoriasis. A qualitative systematic review of the literature.患者与医生对免疫介导的炎症性疾病(类风湿关节炎、银屑病关节炎和银屑病)的认知差异:文献的定性系统评价。
PLoS One. 2020 Jun 17;15(6):e0234705. doi: 10.1371/journal.pone.0234705. eCollection 2020.
2
A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL).一项多国前瞻性观察性研究,旨在评估在真实世界环境中接受生物制剂治疗的中度至重度斑块状银屑病患者的完全皮肤清除情况(PSO-BIO-REAL)。
J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2566-2573. doi: 10.1111/jdv.16568. Epub 2020 Jun 8.
3
Xeligekimab(GR1501)治疗中重度斑块状银屑病患者的疗效和安全性研究:一项多中心、随机、双盲II期临床试验。
Dermatol Ther (Heidelb). 2025 Jun 15. doi: 10.1007/s13555-025-01450-x.
4
Best Responders and Super-Responders to Calcipotriol and Betamethasone Dipropionate PAD-Cream: A Post Hoc Pooled Analysis of Two Phase 3 Trials.卡泊三醇倍他米松二丙酸酯贴剂(PAD乳膏)的最佳反应者和超级反应者:两项3期试验的事后汇总分析
Dermatol Ther (Heidelb). 2025 Jun;15(6):1441-1453. doi: 10.1007/s13555-025-01418-x. Epub 2025 Apr 24.
5
The Real-World Burden of Moderate-to-Severe Psoriasis in Patients Under Systemic Treatment from Baltic Countries: Data from the CRYSTAL Observational Study.波罗的海国家接受系统治疗的中重度银屑病患者的真实世界负担:CRYSTAL观察性研究的数据。
Medicina (Kaunas). 2025 Feb 25;61(3):397. doi: 10.3390/medicina61030397.
6
Real-world experience with brodalumab in a Portuguese cohort of patients with moderate-to-severe psoriasis.在葡萄牙中度至重度银屑病患者队列中使用布罗达单抗的真实世界经验。
Drugs Context. 2025 Mar 14;14. doi: 10.7573/dic.2024-11-4. eCollection 2025.
7
Tildrakizumab Treatment for Psoriasis in Real-world Practice: An Analysis from the Swiss Registry (SDNTT).特诺雅单抗治疗真实世界中银屑病的疗效分析:来自瑞士注册研究(SDNTT)。
Acta Derm Venereol. 2024 Nov 27;104:adv40946. doi: 10.2340/actadv.v104.40946.
8
Bilayered skin equivalent mimicking psoriasis as predictive tool for preclinical treatment studies.双层皮肤等效物模拟银屑病作为临床前治疗研究的预测工具。
Commun Biol. 2024 Nov 18;7(1):1529. doi: 10.1038/s42003-024-07226-x.
9
Disease severity, treatment patterns, and quality of life in patients with moderate-to-severe psoriasis routinely managed with systemic treatment: results of the CRYSTAL observational study in Central and Eastern European countries.中重度银屑病患者接受系统治疗的疾病严重程度、治疗模式和生活质量:CRYSTAL 观察性研究在中东欧国家的结果。
Front Immunol. 2024 May 23;15:1410540. doi: 10.3389/fimmu.2024.1410540. eCollection 2024.
10
Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness.银屑病在难治疗部位的管理挑战:治疗决策与有效性
Life (Basel). 2022 Dec 7;12(12):2050. doi: 10.3390/life12122050.
Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.生物制剂与口服药物治疗斑块状银屑病的比较:一项荟萃分析。
JAMA Dermatol. 2020 Mar 1;156(3):258-269. doi: 10.1001/jamadermatol.2019.4029.
4
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
5
Understanding Treatment Preferences in Patients with Moderate to Severe Plaque Psoriasis in the USA: Results from a Cross-Sectional Patient Survey.了解美国中重度斑块状银屑病患者的治疗偏好:一项横断面患者调查的结果
Dermatol Ther (Heidelb). 2019 Dec;9(4):785-797. doi: 10.1007/s13555-019-00334-1. Epub 2019 Oct 19.
6
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy.联合美国皮肤科学会-国家银屑病基金会关于光疗治疗银屑病的护理和治疗指南。
J Am Acad Dermatol. 2019 Sep;81(3):775-804. doi: 10.1016/j.jaad.2019.04.042. Epub 2019 Jul 25.
7
French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults.法国成人中重度银屑病系统治疗应用指南。
J Eur Acad Dermatol Venereol. 2019 Mar;33(3):464-483. doi: 10.1111/jdv.15340. Epub 2019 Feb 22.
8
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.美国皮肤病学会-银屑病基金会联合指南:生物制剂治疗银屑病的管理与治疗。
J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13.
9
Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review.银屑病患者的治疗偏好和治疗满意度:系统评价。
Arch Dermatol Res. 2018 May;310(4):271-319. doi: 10.1007/s00403-018-1808-x. Epub 2018 Feb 13.
10
A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey.多维度评估银屑病负担:一项来自多国皮肤科医生和患者的调查结果。
Br J Dermatol. 2018 Jul;179(1):173-181. doi: 10.1111/bjd.16332. Epub 2018 Apr 24.